科研动态PubMed 摘要

阿托伐他汀/依折麦布固定剂量复方制剂治疗高胆固醇血症的有效性与安全性:系统评价与网状Meta分析。

PubMed 学科轮询 · 2026-10-21

完整摘要 · 中文译文

背景:许多患者接受他汀类单药治疗未能达到低密度脂蛋白胆固醇(LDL-C)目标,需要他汀类药物与依折麦布联合治疗。本系统评价和网络荟萃分析评估了阿托伐他汀单药治疗、阿托伐他汀/依折麦布自由等效组合(AS/EZ FEC)和固定剂量组合(AS/EZ FDC)在高胆固醇血症患者中的比较有效性和安全性。 方法:从电子数据库中检索随机对照试验。主要结局为LDL-C自基线的百分比变化和LDL-C达标情况,采用均数差(MD)和风险比(RR)及95%置信区间(CI)进行分析。通过累积排序曲线下面积(SUCRA)对治疗进行排序。比较两种联合治疗与单用AS的安全性和耐受性。共纳入46项试验(n = 10,567)。 结果:AS/EZ FDC降低LDL-C的幅度大于单用AS(MD -13.94%,95% CI [-18.90%至-9.10%]),AS/EZ FEC结果相似(MD -12.41%,95% CI [-14.61%至-10.22%])。LDL-C降低的SUCRA排序为FDC(86.2%)、FEC(63.8%)和AS(0.0%)。对于LDL-C达标情况,FEC vs. 单药治疗的RR为1.87(95% CI [1.47-2.39]),FDC vs. 单药治疗的RR为1.80(95% CI [0.85-3.81])。各治疗之间未观察到安全性特征的显著差异。 结论:与AS单药治疗相比,AS/EZ联合治疗在LDL-C降低和达标方面提供更大改善,其中FDC在LDL-C降低方面排序最高。治疗wi 与AS单药治疗相比,第th个AS/EZ FEC或FDC未增加不良事件风险,且耐受性良好。这些发现支持在需要强化LDL-C降低时使用FDC。

完整摘要 · 英文原文

BACKGROUND: Many patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets with statin monotherapy, calling for a combination of statins and ezetimibe. This systematic review and network meta-analysis evaluated the comparative effectiveness and safety of atorvastatin monotherapy, atorvastatin/ezetimibe free-equivalent combination (AS/EZ FEC), and fixed-dose combination (AS/EZ FDC) in patients with hypercholesterolemia. METHODS: Randomized controlled trials were retrieved from electronic databases. Primary outcomes were the percentage change in LDL-C from baseline and LDL-C goal attainment, analyzed using mean difference (MD) and risk ratio (RR) with 95% confidence intervals (CI). Treatments were ranked via surface under the cumulative ranking curve (SUCRA). The two combination therapies were compared to AS alone for their safety profiles and tolerability. Forty-six trials (n = 10,567) were included. RESULTS: AS/EZ FDC reduced LDL-C more than AS alone (MD -13.94%, 95% CI [-18.90% to -9.10%]), with similar results for AS/EZ FEC (MD -12.41%, 95% CI [-14.61% to -10.22%]). SUCRA rankings for LDL-C reduction were FDC (86.2%), FEC (63.8%), and AS (0.0%). For LDL-C goal attainment, the RR was 1.87 (95% CI [1.47-2.39]) for FEC vs. monotherapy, 1.80 (95% CI [0.85-3.81]) for FDC vs. monotherapy. No significant differences in safety profiles were observed between treatments. CONCLUSION: AS/EZ combination therapies provide greater improvements in LDL-C reduction and goal attainment compared with AS monotherapy, with FDC ranking highest in LDL-C reduction. Treatment with AS/EZ FEC or FDC did not increase the risk of adverse events compared to AS monotherapy and was well tolerated. These findings support FDC use when intensive LDL-C lowering is required.

English
Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界